EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters

Xiaoting Tu, Hongyan Ren, Shurui Bu

Frontiers in Microbiology · 14.12.2023 · 14

DOI: 10.3389/fmicb.2023.1274559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 14.12.2023. Verfasst von Xiaoting Tu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Jinshan Hospital Affiliated to Fudan University, Shanghai, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Constipation-predominant irritable bowel syndrome (IBS-C) is a functional bowel disease that affects 10–20% of the population worldwide. Curcumin (CUR) is widely used in traditional Chinese medicine to treat IBS, but its mechanism of action needs further investigation.

Methods

In this study, we used mosapride (MOS) as a positive control to evaluate the changes in gut microbiota in IBS-C rat models after treatment with CUR or MOS by analyzing 16S rDNA variation. In addition, we used enzyme immunoassay kits and immunohistochemical analysis to investigate whether CUR or MOS influenced serotonin (5-HT), substance P (SP), and vasoactive intestinal peptide (VIP) levels in the serum and colon of IBS-C rats.

Results

The study showed that rats supplemented with CUR showed significantly increased fecal weight, fecal water content, small intestine transit rate and significantly decreased serum levels of 5-HT, VIP and SP compared to the IBS group ( p < 0.05). In addition, treatment with CUR changed the relative abundance of Blautia , Sutterella , Acetanaerobacterium and Ruminococcus 2 in the gut microbiota.

Discussion

This study showed that the efficacy of CUR on IBS-C was possibly by modulating the microbiota and lowering the serum levels of HT, SP, and VIP.

Schlagwörter

Stichwörter der Autor:innen

constipationcurcumingut microbiotairritable bowel syndromeneurotransmitters

Autor:innen und Institutionen

  • Department of Gastroenterology, Jinshan Hospital Affiliated to Fudan University, Shanghai, China.
  • Shanghai Mobio Biomedical Technology Co. Ltd., Shanghai, China.

Zitieren

APA

Tu, X., Ren, H., & Bu, S. (2023). Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1274559

Vancouver

Tu X, Ren H, Bu S. Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1274559

BibTeX
@article{Tu2023,
  author = {Tu, Xiaoting and Ren, Hongyan and Bu, Shurui},
  title = {Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1274559}
}
Kostenlos starten →